Abstract: A process can be used for preparing nanoparticles containing at least one bio-resorbable polyester. The nanoparticles are in the form of a powder with a Z-Average particle size Dz in the range of 1 to 450 nm, and with a polydispersity index PDI in the range of 0.01 to 0.5. The process involves emulsion-solvent extraction or emulsion-solvent evaporation, and application of ultrasonic sound.

Abstract: Methods, systems, and apparatus, including computer programs encoded on computer storage media, for generating a prediction of an audio signal. One of the methods includes receiving a request to generate an audio signal conditioned on an input; processing the input using an embedding neural network to map the input to one or more embedding tokens; generating a semantic representation of the audio signal; generating, using one or more generative neural networks and conditioned on at least the semantic representation and the embedding tokens, an acoustic representation of the audio signal; and processing at least the acoustic representation using a decoder neural network to generate the prediction of the audio signal.

Abstract: Methods, systems, and apparatus, including computer programs encoded on computer storage media, for generating a prediction of an audio signal. One of the methods includes receiving a request to generate an audio signal conditioned on an input; processing the input using an embedding neural network to map the input to one or more embedding tokens; generating a semantic representation of the audio signal; generating, using one or more generative neural networks and conditioned on at least the semantic representation and the embedding tokens, an acoustic representation of the audio signal; and processing at least the acoustic representation using a decoder neural network to generate the prediction of the audio signal.

Abstract: A process can be used for preparing nano- or microparticles containing a carrier-polymer and a biologically active ingredient. The process is a solvent emulsion process involving an organic phase (OP) and an aqueous phase (AP) to form an emulsion. In the case of an oil-in-water emulsion (O/W), the organic phase (OP) contains the biologically active ingredient dissolved or dispersed therein. Alternatively, in the case of a water-in-oil emulsion (W1/O), the aqueous phase (AP) contains the biologically active ingredient dissolved or dispersed therein. The organic phase (OP) is saturated with the salt-containing aqueous phase (AP) and vice versa.

Abstract: A knee airbag having a first wall extending from an upper end and having a first outer surface serving as an impact surface being positioned opposite the knee-shin-area of an occupant to be protected when the airbag is fully deployed, and a second wall extending from a rear end adjacent or identical to the upper end of the first wall and having a second outer surface. The second wall comprises a first section, a second section and a groove section being positioned between the first section and the second section such that the second outer surface shows a groove. In order to make the knee airbag suitable for a vehicle that does not provide sufficient instrument panel surface to support it, the first wall and the first and second sections of the second wall enclose an angle between 20° and 80°, preferably between 30° and 60°.

Abstract: The present invention is related to a composition for use in reducing inflammation, wherein the composition comprises at least one keto acid and/or a salt thereof, preferably selected from the branched chain keto acids keto leucine, keto valine and keto isoleucine.

Abstract: A control and data transfer system for supporting different communication protocols, in which the system includes a control device that can store a plurality of different communication protocols. The control device is adapted for loading and executing at least one of the stored communication protocols. Further, a first adapter module is connectable to the control device. The first adapter module includes an identification device which enables the control device to identify the first communication protocol, and a communications interface for connecting, to the first adapter module, at least one first device that is configured for communication according to one of the stored communication protocols. The control and evaluation device is configured to use the identification device for identifying the first communication protocol when the first adapter module is connected to the control device, and to load and execute the identified first communication protocol from the storage device.

Abstract: A pharmaceutical composition contains at least one methacrylic copolymer having units derived from methacrylamide; at least one pharmaceutically active ingredient; at least one lipid component; and at least one surfactant. The pharmaceutical composition can be used as a medicament. A method can be used to prepare a solid self-nanoemulsifying drug delivery system using the different compounds of the pharmaceutical composition.

Abstract: A process can be used for preparing nano- or microparticles containing a carrier-polymer and a biologically active ingredient. The process is a solvent emulsion process involving an organic phase (OP) and an aqueous phase (AP) to form an emulsion. In the case of an oil-in-water emulsion (O/W), the organic phase (OP) contains the biologically active ingredient dissolved or dispersed therein. Alternatively, in the case of a water-in-oil emulsion (W1/O), the aqueous phase (AP) contains the biologically active ingredient dissolved or dispersed therein. The organic phase (OP) is saturated with the salt-containing aqueous phase (AP) and vice versa.

Abstract: A process can be used for preparing nanoparticles containing at least one bio-resorbable polyester. The nanoparticles are in the form of a powder with a Z-Average particle size D, in the range of 3 to 450 nm, and with a polydispersity index PDI in the range of 0.01 to 0.5. The process involves emulsion-solvent extraction or emulsion-solvent evaporation, and application of ultrasonic sound.

Abstract: A method of unambiguous identification and authentication of products for the purpose of better recognition of product forgeries and controlling product piracy, including applying to/into the product an identification substance admixture which contains paramagnetic phases or identifying a product which contains an identification substance admixture containing paramagnetic phases and has an ESR fingerprint spectrum that permits unambiguous identification of the product. Such an ESR fingerprint spectrum is easily measurable, but can be copied or forged only with difficulty. The method relates to an individualizable “femto tag” for femto ledgers and forms an important interface for what are known as “Internet of Things” (IOT).

Abstract: A knee airbag having a first wall extending from an upper end and having a first outer surface serving as an impact surface being positioned opposite the knee-shin-area of an occupant to be protected when the airbag is fully deployed, and a second wall extending from a rear end adjacent or identical to the upper end of the first wall and having a second outer surface. The second wall comprises a first section, a second section and a groove section being positioned between the first section and the second section such that the second outer surface shows a groove. In order to make the knee airbag suitable for a vehicle that does not provide sufficient instrument panel surface to support it, the first wall and the first and second sections of the second wall enclose an angle between 20° and 80°, preferably between 30° and 60°.

Abstract: A composition may be used in treating or preventing a virus infection in a subject, wherein the virus is from the Paramyxoviridae family and wherein the composition includes an extract of black currants and bilberries. The composition may contain an extract from black currants and bilberries in a weight ratio in a range of from 0.5:1 to 1:0.5. The extract may be an alcoholic extract, such as a methanol extract. The composition may be administered to the subject 1 to 10 oral dosages of at least 80 mg anthocyanins each per day, preferably 3 to 6 oral dosages of at least 80 mg anthocyanins each per day. The subject may not have received a measles vaccination or have previously been exposed to the measles virus.

Abstract: The present invention is related to Delphinidin-3-glucoside (D3G) for use in treating or preventing a vims infection in a subject, wherein the virus is from the Herpesviridae family.

Abstract: Combined preparations including an anthocyanin composition and an antiviral agent for use in treating or preventing a virus infection in a subject, wherein the anthocyanin composition includes an extract of black currants, an extract of bilberries, an extract of red grapes, and/or delphinidin 3 glucoside, wherein the virus is from the Herpesviridae family and the antiviral agent is a Herpesviridae antiviral agent, and wherein the anthocyanin composition and the antiviral agent are for simultaneous, separate or sequential use.

Abstract: A control and data transfer system for supporting different communication protocols, in which the system includes a control device that can store a plurality of different communication protocols. The control device is adapted for loading and executing at least one of the stored communication protocols. Further, a first adapter module is connectable to the control device. The first adapter module includes an identification device which enables the control device to identify the first communication protocol, and a communications interface for connecting, to the first adapter module, at least one first device that is configured for communication according to one of the stored communication protocols. The control and evaluation device is configured to use the identification device for identifying the first communication protocol when the first adapter module is connected to the control device, and to load and execute the identified first communication protocol from the storage device.

Abstract: A microwave connector assembly comprises a waveguide ferrule having a receiving end receiving a dielectric waveguide, a connecting end distal to the receiving end, and a locking member, and a ferrule socket at least partially receiving the waveguide ferrule in a ferrule receptacle. The ferrule socket engages in a locking connection with the locking member. The ferrule socket has a coding member engaging a complementary coding member of the waveguide ferrule only when the waveguide ferrule is positioned relative to the ferrule socket in a single predetermined angular position or in one of two predetermined angular positions that are rotated by 180° with respect to each other.

Abstract: A process prepares a polymer powder, with a D50 particle size from 40 to 200 ?m and a Hausner factor of 1.25 or less, by freeze drying and subsequent loosening up of an aqueous polymer dispersion containing 15 to 50% by weight of a polymer. The polymer is polymerized from 10 to 30% by weight of methyl methacrylate, 50 to 70% by weight of methyl acrylate, and 5 to 15% by weight of methacrylic acid.

Abstract: A process prepares a polymer powder, with a D50 particle size from 40 to 200 ?m and a Hausner factor of 1.25 or less, by freeze drying and subsequent loosening up of an aqueous polymer dispersion containing 15 to 50% by weight of a polymer. The polymer is polymerized from 10 to 30% by weight of methyl methacrylate, 50 to 70% by weight of methyl acrylate, and 5 to 15% by weight of methacrylic acid.

Abstract: A nanoparticle includes a core. The core includes a bio-resorbable polyester and a hydrophilic polymer. The hydrophilic polymer is a portion of the bio-resorbable polyester or a separate polymer. An acylated human lactoferrin-derived peptide is coated onto the core. The acylated human lactoferrin-derived peptide is a peptide with the amino acid sequence SEQ ID NO. 1: KCFQWQRNMRKVRGPPVSCIKR or an amino acid sequence, which does not differ by more than 8 amino acid positions from the sequence SEQ ID NO: 1. The N-terminus of the human lactoferrin-derived peptide is acylated with a C16-monoacyl group.